MNO-863 / Moon (Guangzhou) Biotech - LARVOL DELTA

Christensenella intestinihominis MNO-863 improve obesity and related metabolic disorders via SCFAs-induced GLP-1 hormone secretion. (PubMed, Front Nutr) - "The anti-obesity efficacy of MNO-863 monotherapy is comparable to that of Liraglutide (GLP-1 analogue), and the combination of MNO-863 and Liraglutide has potential synergistic anti-obesity therapeutic effect. A 28-day oral toxicity study in Sprague Dawley (SD) rats showed that MNO-863 Fermental Powder at doses up to 1.2 × 1012 colony-forming unit (CFU)/animal/day caused no observed adverse effects. As a second-generation probiotic, MNO-863 is expected to provide a new, safer drug option for patients with obesity and related complications."

Journal • Addiction (Opioid and Alcohol) • Diabetes • Dyslipidemia • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity